Kintara CFO resigns; CEO Hoffman takes interim CFO role; expects VAL-083 data by Q4 2023

TuHURA Biosciences, Inc./NV

Scott Praill resigned as CFO effective May 31, 2023; will consult for 2 months at $5,000/month.
CEO Robert Hoffman appointed interim CFO (retaining CEO/Chairman roles), effective June 1, 2023.
Hoffman voluntarily reduced base salary by $60,000 indefinitely; granted 59,800 RSUs vesting June 1, 2024.
Company expects results of GBM AGILE study for VAL-083 before end of Q4 2023.
Expense reductions extend projected cash runway through anticipated data readout date.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Scott Praill

Chief Financial Officer

HURA · TuHURA Biosciences, Inc./NV

Effective: 2023-05-31
Successor: Robert E. Hoffman
Filed: June 2, 2023, 7:59 PM ET

On May 30, 2023, Scott Praill resigned from his position as Chief Financial Officer of Kintara Therapeutics, Inc. (the “Company”), effective May 31, 2023.

Appointed (interim)

Robert E. Hoffman

interim Chief Financial Officer

HURA · TuHURA Biosciences, Inc./NV

Effective: 2023-06-01
Filed: June 2, 2023, 7:59 PM ET

On June 1, 2023, the Company’s Board of Directors (the “Board”) appointed Robert E. Hoffman, the current President, Chief Executive Officer, and Chairman of the Board of the Company, to succeed Mr. Praill as the Company’s interim Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Praill resigned as Chief Financial Officer at TuHURA Biosciences, Inc./NV.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On May 30, 2023, Scott Praill resigned from his position as Chief Financial Officer of Kintara Therapeutics, Inc. (the “Company”), effective May 31, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Hoffman was appointed as interim Chief Financial Officer at TuHURA Biosciences, Inc./NV.

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

On June 1, 2023, the Company’s Board of Directors (the “Board”) appointed Robert E. Hoffman, the current President, Chief Executive Officer, and Chairman of the Board of the Company, to succeed Mr. Praill as the Company’s interim Chief Financial Officer.

View on SEC.gov

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-025898

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.